Company intelligence / Profile preview
Aera Therapeutics
Cambridge, Massachusetts, USAaeratx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Aera Therapeutics has not yet reported clinical results. The company remains in the preclinical/research stage, focusing on developing proprietary protein and lipid nanoparticle platforms for the targeted delivery of genetic medicines, including CRISPR-based therapies.
- Therapeutic areas
- Other
- Modalities
- siRNA (small interfering RNA)ASOs (antisense oligonucleotides)mRNA (messenger RNA)DNAGene editing systems/CRISPR-based platformsProtein nanoparticle delivery systems (PNPs)Lipid nanoparticle delivery systems (LNPs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Aera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aera Therapeutics.